Core Insights - Daxor Corporation is a leader in blood volume measurement technology, showcasing its innovative BVA technology at the AAHFN Annual Meeting, emphasizing its potential to improve heart failure management and overall cardiovascular care [1][2] - The BVA-100® is the only FDA-cleared diagnostic blood test for accurate blood volume status and composition, with over 65,000 tests performed, significantly reducing mortality and readmissions in heart failure and critical care [1] - Daxor is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [1] Event Participation - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, in Orlando, Florida, aimed at advancing nursing education and improving heart failure patient outcomes [2]
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting